Keyphrases
Acquired Resistance Mechanism
14%
Agent Strategies
14%
Alpelisib
14%
Anastrozole
14%
Aromatase Inhibitors
14%
Breast Cancer Susceptibility Gene 1 (BRCA1)
14%
Clinical Trials
14%
Combination Strategy
14%
Cyclin-dependent Kinase 4 (CDK4)
28%
Cyclin-dependent Kinase 4/6 Inhibitors
14%
Disease Progression
14%
Endocrine Resistance
14%
Endocrine Therapy
57%
Epigenetic Biomarkers
14%
ER Signaling
14%
Estrogen Receptor 1 (ESR1)
14%
Estrogen Receptor alpha Gene
14%
Everolimus
14%
Exemestane
28%
Fulvestrant
85%
Germ Cells
14%
Hormone Receptor-positive
100%
Human Epidermal Growth Factor Receptor 2-negative
100%
Inhibit Tumor
14%
Intrinsic Resistance
14%
Letrozole
14%
Metastatic Breast Cancer
100%
MTOR Inhibitor
14%
New Standards
14%
Optimal Sequence
14%
Overall Survival
14%
Phosphatidylinositol 4-phosphate 5-kinase (PIP5K)
14%
PIK3CA
14%
PIK3CA mutation
14%
Postmenopausal Patients
14%
Practical Guidance
14%
Progression-free Survival
14%
Resistant Disease
14%
Selective Estrogen Receptor Modulators
28%
Standard of Care
14%
Targeted Agents
14%
Targeted Combination
14%
Treatment Landscape
14%
Tumor Cell Proliferation
14%
Pharmacology, Toxicology and Pharmaceutical Science
Alpelisib
14%
Anastrozole
14%
Aromatase Inhibitor
14%
Biological Marker
14%
Breast Cancer
14%
Clinical Trial
14%
Cyclin Dependent Kinase 4
14%
Disease Exacerbation
14%
Diseases
14%
Endocrine Therapy
57%
Epidermal Growth Factor Receptor 2
100%
Estrogen Receptor
14%
Estrogen Receptor Alpha
14%
Everolimus
14%
Exemestane
28%
Fulvestrant
85%
Gamma Urogastrone
100%
Hormone Receptor
100%
Letrozole
14%
Mammalian Target of Rapamycin Inhibitor
14%
Metastatic Breast Cancer
100%
Neoplasm
14%
Overall Survival
14%
Phosphatidylinositol 4,5 Bisphosphate 3 Kinase
14%
Progression Free Survival
14%
Selective Estrogen Receptor Modulator
14%
Tamoxifen
14%